ストックスクリーナーアプリを入手
13.18
2.80%
-0.38
前日終値:
$13.56
開ける：
$13.61
24時間の取引高:
913.54K
Relative Volume:
0.45
時価総額：
$1.18B
収益：
$139.71M
当期純損益:
$-209.36M
株価収益率:
-4.4527
EPS:
-2.96
ネットキャッシュフロー:
$-160.60M
1週間 パフォーマンス:
-3.87%
1か月 パフォーマンス:
-13.74%
6か月 パフォーマンス:
-30.23%
1年 パフォーマンス:
-44.62%
1日の値動き範囲:
$12.95
$13.80
1週間の範囲:
$12.70
$13.97
52週間の値動き範囲:
$12.06
$25.07
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
名前
Syndax Pharmaceuticals Inc
セクター
電話
781-419-1400
住所
35 GATEHOUSE DRIVE, WALTHAM, MA
SNDX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
13.18 | 1.18B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-06-28 | 開始されました | Jefferies | Buy |
| 2024-01-31 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | 開始されました | Mizuho | Buy |
| 2023-10-25 | 開始されました | BofA Securities | Buy |
| 2023-10-11 | 開始されました | Goldman | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
| 2023-07-11 | 開始されました | Guggenheim | Buy |
| 2023-04-17 | 再開されました | BTIG Research | Buy |
| 2023-01-31 | 開始されました | Stifel | Buy |
| 2023-01-03 | 開始されました | JP Morgan | Overweight |
| 2022-07-28 | 再開されました | B. Riley Securities | Buy |
| 2022-04-11 | 開始されました | H.C. Wainwright | Buy |
| 2022-02-15 | 開始されました | Goldman | Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-05-25 | 開始されました | Citigroup | Buy |
| 2021-02-18 | 開始されました | B. Riley Securities | Buy |
| 2020-12-03 | 開始されました | Stifel | Buy |
| 2020-05-22 | アップグレード | Citigroup | Neutral → Buy |
| 2020-05-22 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-05-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-03-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-01-04 | 開始されました | Robert W. Baird | Outperform |
| 2018-01-05 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | 開始されました | FBR & Co. | Outperform |
| 2017-03-02 | 開始されました | Instinet | Buy |
| 2016-10-07 | 開始されました | Guggenheim | Buy |
| 2016-03-28 | 開始されました | Citigroup | Buy |
| 2016-03-28 | 開始されました | JMP Securities | Mkt Outperform |
| 2016-03-28 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Syndax Pharmaceuticals Inc (SNDX) 最新ニュース
Simplify Asset Management Inc. Purchases 25,456 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
What Do Analysts Think About Syndax Pharmaceuticals Inc’s (NASDAQ:SNDX) Future? - Stocks Register
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $41.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Long Term Trading Analysis for (SNDX) - Stock Traders Daily
Charles Schwab Investment Management Inc. Purchases 8,876 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 5.5% Following Analyst Upgrade - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $41.00 - Defense World
Syndax Pharmaceuticals’ 41% decline validates InvestingPro’s bearish call By Investing.com - Investing.com UK
Syndax's Revuforj Earns Strong Physician Support, JP Morgan Predicts Sales Growth - Benzinga
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 5.5% on Analyst Upgrade - Defense World
Bank of New York Mellon Corp Increases Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
US Bancorp DE Reduces Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $36.00 Average Price Target from Analysts - MarketBeat
Syndax at Barclays Healthcare Conference: Strategic Vision for Menin Inhibitors - Investing.com UK
Syndax Pharmaceuticals’ SWOT analysis: stock soars on FDA approvals, faces profitability hurdles - Investing.com India
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Syndax Pharmaceuticals’ SWOT analysis: stock soars on FDA approvals, faces profitability hurdles By Investing.com - Investing.com South Africa
Graft Versus Host Disease Market Expected to rise, 2034 | Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio - The Globe and Mail
Candriam S.C.A. Cuts Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
What Does Syndax Pharmaceuticals Inc’s (NASDAQ: SNDX) Future Hold? - Stocks Register
What is B. Riley's Forecast for SNDX Q3 Earnings? - MarketBeat
What is HC Wainwright's Forecast for SNDX FY2025 Earnings? - MarketBeat
What is HC Wainwright's Forecast for SNDX Q1 Earnings? - MarketBeat
Q1 Earnings Forecast for SNDX Issued By B. Riley - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 7.4% Following Weak Earnings - MarketBeat
JPMorgan Chase & Co. Issues Positive Forecast for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price - MarketBeat
Citigroup Issues Pessimistic Forecast for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price - MarketBeat
Syndax Pharmaceuticals' (SNDX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Syndax Pharmaceuticals Reports 2024 Financial Results - MSN
Syndax Pharmaceuticals Inc to Host Earnings Call - ACCESS Newswire
What is B. Riley’s Estimate for SNDX Q3 Earnings? - Defense World
What is HC Wainwright’s Forecast for SNDX FY2025 Earnings? - Defense World
Syndax Pharmaceuticals (NASDAQ:SNDX) Announces Quarterly Earnings Results - MarketBeat
Strong Buy Rating for Syndax Pharmaceuticals Driven by Revuforj’s Market Potential and Revenue Growth - TipRanks
HC Wainwright Reiterates “Buy” Rating for Syndax Pharmaceuticals (NASDAQ:SNDX) - Defense World
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - Defense World
Citigroup Lowers Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $42.00 - Defense World
Syndax Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
What is B. Riley’s Forecast for SNDX Q1 Earnings? - Defense World
What is HC Wainwright’s Forecast for SNDX Q1 Earnings? - Defense World
Syndax Pharmaceuticals Inc (SNDX) Q4 2024 Earnings Call Highlights: Strong Product Launch and ... By GuruFocus - Investing.com Canada
Syndax Pharmaceuticals’ Earnings Call Highlights Key Milestones - TipRanks
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Syndax Pharmaceuticals Inc (SNDX) 財務データ
収益
当期純利益
現金流量
EPS
Syndax Pharmaceuticals Inc (SNDX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Metzger Michael A | Chief Executive Officer |
Mar 04 '25 |
Option Exercise |
7.20 |
7,814 |
56,261 |
307,935 |
| Metzger Michael A | Chief Executive Officer |
Mar 04 '25 |
Sale |
15.05 |
7,814 |
117,564 |
300,121 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):